Axonal protection in multiple sclerosis--a particular need during remyelination?
Smith
Kenneth J
KJ
Department of Clinical Neurosciences, Institute of Psychiatry, King's College London, 19 Newcomen Street, London, SE1 1UL, UK. kenneth.smith@kcl.ac.uk
D000255:Adenosine Triphosphate / Q000378:metabolism; D001369:Axons / Q000502:physiology*; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000503:physiopathology*; D009186:Myelin Sheath / Q000502:physiology; D009410:Nerve Degeneration / Q000503:physiopathology / Q000517:prevention & control; D009413:Nerve Fibers, Myelinated / Q000502:physiology; D009569:Nitric Oxide / Q000378:metabolism; D026941:Sodium Channel Blockers / Q000627:therapeutic use*; D015222:Sodium Channels / Q000378:metabolism
D026941:Sodium Channel Blockers; D015222:Sodium Channels; D009569:Nitric Oxide; D000255:Adenosine Triphosphate